A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-12-06
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the efficacy of E7777 in participants with recurrent
or persistent Cutaneous T-Cell Lymphoma (CTCL) in Stage I - III participants as assessed by
objective response rate (ORR). A lead-in dose-finding part was used to determine dose level 9
microgram per kilogram (mcg/kg) E7777 that is being used to test efficacy and safety.